Get the Stockscreener App
226.48
0.23%
-0.52
After Hours:
226.62
0.14
+0.06%
Ascendis Pharma A S stock is traded at $226.48, with a volume of 298.45K.
It is down -0.23% in the last 24 hours and down -5.54% over the past month.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
See More
Previous Close:
$227.00
Open:
$230.4
24h Volume:
298.45K
Relative Volume:
0.37
Market Cap:
$14.90B
Revenue:
$1.01B
Net Income/Loss:
$581.90M
P/E Ratio:
25.52
EPS:
8.8733
Net Cash Flow:
$50.57M
1W Performance:
+1.70%
1M Performance:
-5.54%
6M Performance:
-6.30%
1Y Performance:
+9.35%
1-Day Range:
$226.06
$234.01
1-Week Range:
$222.00
$234.01
52-Week Range:
$186.05
$282.15
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
226.48 | 14.90B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-26 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-27-26 | Initiated | H.C. Wainwright | Buy |
| Aug-19-26 | Initiated | BMO Capital Markets | Outperform |
| May-19-26 | Initiated | Citigroup | Buy |
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-25 | Initiated | Raymond James | Strong Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-05-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-16-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | UBS | Buy |
| Sep-05-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-25-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Initiated | Stifel | Buy |
| Dec-20-23 | Initiated | Jefferies | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Neutral |
| Apr-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-04-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-03-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Aug-30-22 | Resumed | Berenberg | Buy |
| Mar-28-22 | Resumed | Wedbush | Outperform |
| Mar-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-14-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-06-22 | Initiated | Cowen | Market Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-20-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-30-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-11-21 | Resumed | Stifel | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Mar-20-20 | Initiated | Oppenheimer | Outperform |
| Oct-11-19 | Initiated | Morgan Stanley | Overweight |
| Mar-25-19 | Initiated | Evercore ISI | Outperform |
| Jan-24-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-19 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-18 | Initiated | Stifel | Buy |
| Apr-02-18 | Reiterated | Leerink Partners | Mkt Perform |
| May-11-17 | Initiated | JP Morgan | Overweight |
| Mar-09-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Feb-09-17 | Initiated | Credit Suisse | Outperform |
| Sep-26-16 | Initiated | Wedbush | Outperform |
View All
Ascendis Pharma A S Stock (ASND) Latest News
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing - Zacks Investment Research
Ascendis Pharma (NasdaqGS:ASND) Stock Price - Simply Wall Street
Ascendis Pharma (ASND) Authorizes $400M Share Buyback - finance.yahoo.com
Ascendis Pharma (NASDAQ: ASND) board okays discretionary $400M share buyback - Stock Titan
Ascendis Pharma Authorizes Up to $400 Million Share Repurchase Program - Quiver Quantitative
Ascendis Announces Planned $400 Million Share Repurchase Program - GlobeNewswire
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - Yahoo Finance
Ascendis Pharma (ASND) ReACHin Data Keeps The Bull Case Alive As Valuation Questions Linger - simplywall.st
TD Cowen reiterates Buy on Ascendis Pharma stock on infant data By Investing.com - Investing.com Nigeria
Ascendis Pharma (NASDAQ: ASND) Issues 29,380 Employee Warrants at $270.09 Exercise Price - Kalkine Media
Insider Decision: Mads Bodenhoff Offloads $810K Worth Of Ascendis Pharma Stock - Benzinga
Ascendis Pharma Says Growth Drug Shows Benefits in Infants - Benzinga
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy - Investing.com
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com UK
TD Cowen reiterates Buy on Ascendis Pharma stock on infant data - investing.com
TD Cowen reiterates Buy on Ascendis Pharma stock on infant data - Investing.com
BMO reiterates Ascendis Pharma stock rating on infant trial data - investing.com
BMO reiterates Ascendis Pharma stock rating on infant trial data By Investing.com - Investing.com India
BMO reiterates Ascendis Pharma stock rating on infant trial data By Investing.com - Investing.com Canada
BMO reiterates Ascendis Pharma stock rating on infant trial data - Investing.com
Ascendis Pharma SVP Mads Bodenhoff Exercises Warrants and Sells 3,000 Shares on September 8, 2026 - Kalkine Media
Early infant trial hints at spine and growth gains, Ascendis Pharma (NASDAQ: ASND) says - Stock Titan
Ascendis Pharma SVP & Pao Sold Shares Worth Over $810K - TradingView
Ascendis Pharma (ASND) officer cashes 3K warrants, sells matching shares - Stock Titan
Ascendis Pharma (NASDAQ: ASND) prices new employee warrants at $270.09 - Stock Titan
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026 - GlobeNewswire
Ascendis Pharma (NASDAQ:ASND): A Fitting Candidate for Affordable Growth Investors - ChartMill
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC - Yahoo Finance
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - The Manila Times
Ascendis Pharma (NASDAQ: ASND) officer lines up 3,000-ADS sale for 2026 - Stock Titan
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - finance.yahoo.com
Ascendis to Present Navepegritide Infant Trial Data at ESPE 2026 - The Clinical Trial Vanguard
Ascendis Pharma A/S Trade Ideas — HAM:A710 - TradingView
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 - The Manila Times
Ascendis Pharma to Present Sentinel Cohort Data from reACHin Trial of TransCon CNP at ESPE 2026 - Quiver Quantitative
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 - GlobeNewswire
Ascendis Pharma A/S (ASND) Stock Analysis: Unveiling a 16.35% Potential Upside for Investors - DirectorsTalk Interviews
Ascendis Pharma (ASND) Could Be 14% Undervalued Following Yorvipath Reimbursement Progress - simplywall.st
Ascendis Pharma (ASND) Reimbursement Win Puts Its Fair Value Narrative Back In Focus - Yahoo Finance
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing - Yahoo Finance
Ascendis Pharma Director Lars Holtug Executes Sale of 236 Shares at $264.13 Each - Kalkine Media
Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $312 - Moomoo
Ascendis Pharma (ASND) director sells 236 shares in open-market trade - Stock Titan
Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND) - The Globe and Mail
Ascendis Pharma (ASND) director to sell shares for taxes - Stock Titan
Oppenheimer Adjusts Price Target on Ascendis Pharma to $312 From $304, Maintains Outperform Rating - marketscreener.com
Stifel Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $326 - Moomoo
Ascendis Pharma A/S (ASND) Institutional Ownership 2026 - MarketBeat
Ascendis Pharma A S Stock (ASND) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ascendis Pharma A S Stock (ASND) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bodenhoff Mads | SVP & PAO |
Sep 08 '26 |
Sale |
270.19 |
3,000 |
810,570 |
0 |
| Bodenhoff Mads | Officer |
Sep 08 '26 |
Proposed Sale |
270.19 |
3,000 |
810,563 |
0 |
| HOLTUG LARS | Director |
Sep 02 '26 |
Sale |
264.13 |
236 |
62,335 |
4,000 |
| HOLTUG LARS | Director |
Sep 02 '26 |
Proposed Sale |
264.13 |
236 |
62,335 |
0 |
| BIENAIME JEAN JACQUES | Director |
Aug 14 '26 |
Buy |
246.33 |
2,000 |
492,654 |
2,900 |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer |
Jun 02 '26 |
Buy |
219.00 |
100 |
21,900 |
4,367 |
| BIENAIME JEAN JACQUES | Director |
May 29 '26 |
Buy |
223.12 |
500 |
111,562 |
900 |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer |
May 29 '26 |
Buy |
223.32 |
250 |
55,830 |
4,267 |
| BIENAIME JEAN JACQUES | Director |
May 26 '26 |
Buy |
237.80 |
400 |
95,120 |
400 |
| JENSEN FLEMMING STEEN | See Remarks |
May 11 '26 |
Sale |
238.49 |
19,460 |
4,641,021 |
0 |
3.02%
2.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):